Judge Your Health

Novo Nordisk and His & Hers Health have formed a new alliance to sell obesity medications after resolving their legal disputes. The program provides patients with access to Novo Nordisk's well-known GLP-1 weight loss medications, such as Vegovy and Ozempic, via Hims' telemedicine platform. Due to patent and safety issues, Novo Nordisk sued Himes for marketing mixed formulations of semaglutide, the active component in these medications. As part of the new agreement, Himes will